Elanco Animal Health (ELAN) vs Madrigal Pharmaceuticals (MDGL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Elanco Animal Health (ELAN) has outperformed Madrigal Pharmaceuticals (MDGL) over the past year, gaining 10.8% versus a gain of 9.1%. Over five years, MDGL leads with a +453.5% price change compared with -30.7% for ELAN. Elanco Animal Health is the larger company by market cap ($11.26 billion vs $11.02 billion), about 1.0 times the size, while Madrigal Pharmaceuticals is growing revenue faster (+432.1% vs +6.2%).
On valuation, Elanco Animal Health trades at a lower forward P/E (17.5x vs 49.5x for Madrigal Pharmaceuticals). Elanco Animal Health converts more of its revenue into profit, with a net margin of -4.9% versus -30.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ELAN | MDGL |
|---|---|---|
| Share price | $22.54 | $476.91 |
| Market cap | $11.26B | $11.02B |
| 1-day change | +0.81% | -2.22% |
| YTD return | -0.40% | -18.10% |
| 1-year return | +10.82% | +9.15% |
| 5-year return | -30.73% | +453.45% |
| Forward P/E | 17.54 | 49.55 |
| EPS (TTM) | $-0.41 | $-12.85 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $4.71B | $958.40M |
| Revenue growth (YoY) | +6.22% | +432.05% |
| Net income (latest FY) | $-232.00M | $-288.28M |
| Gross margin | 54.99% | — |
| Operating margin | — | -31.31% |
| Net margin | -4.92% | -30.08% |
| 52-week high | $27.98 | $615.00 |
| 52-week low | $19.40 | $393.61 |
| Distance from 52-week high | -19.44% | -22.45% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +37.53% | +43.03% |
| Average volume | 6.19M | 289.24K |
| Shares outstanding | 499.45M | 23.10M |
| Employees | 9,400 | 915 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Elanco Animal Health is more profitable, keeping -4.9 cents of every revenue dollar as net income versus -30.1 cents for Madrigal Pharmaceuticals.
- Madrigal Pharmaceuticals grew revenue faster in its latest fiscal year (+432.05% vs +6.22%).
About Elanco Animal Health
ELAN stock →Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. The company offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio Family, Interceptor Plus, Drontal family, and Drontal Plus; vaccines portfolio that provides differentiated prevention coverage for a number of important pet health risks; and therapeutics portfolio for the treatment of pain, otitis, cardiovascular, and dermatology indications, as well as osteoarthritis for dogs and cats under the Galliprant trademark.
Health Care · Biotechnology: Pharmaceutical Preparations · 9,400 employees
About Madrigal Pharmaceuticals
MDGL stock →Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH.
Health Care · Biotechnology: Pharmaceutical Preparations · 915 employees
ELAN vs MDGL FAQ
Which is bigger, Elanco Animal Health or Madrigal Pharmaceuticals?
Elanco Animal Health (ELAN) is larger, with a market capitalization of $11.26B compared with $11.02B for Madrigal Pharmaceuticals (MDGL).
Which stock has performed better over the past year, ELAN or MDGL?
ELAN returned +10.82% over the past 12 months, compared with +9.15% for MDGL (price return, excluding dividends). Past performance does not predict future results.
Are Elanco Animal Health and Madrigal Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.